RemeGen & Santen Announce CDE Acceptance of RC28‑E for Diabetic Macular Edema
China‑based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) and Japan’s Santen Pharmaceutical Co., Ltd. confirmed...
SHA: 688331
RemeGen’s Telitacicept Hits Primary Endpoint in Phase III IgA Nephropathy Trial
China‑based RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) on Aug, 27, 2025announced that its first‑in‑class BLyS/APRIL...
RemeGen Reports 48% Revenue Growth in 2025 H1 Driven by Telitacicept and Disitamab Vedotin
RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based biotech company, reported its 2025 semi-annual...
RemeGen’s RC148 Granted Breakthrough Therapy Designation for NSCLC Treatment
RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based biotech company, announced that its novel...
RemeGen Inks Licensing Deal With Santen China for RC28-E Eye Disease Drug
China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced an agreement with Santen China, a...
RemeGen Announces Positive Phase III Results for Telitacicept in Primary Sjögren’s Syndrome
China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based pharmaceutical firm, announced on August...
RemeGen Inks Global Licensing Pact With Vor Biopharma for Telitacicept
China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced an exclusive licensing agreement with U.S.-based...
RemeGen’s Telitacicept Receives Orphan Drug Designation for Myasthenia Gravis in Europe
China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced that it has received orphan drug...
RemeGen’s 2024 Revenue Soars 58.54% on Strong Product Sales and R&D Growth
China-based biotech RemeGen Co., Ltd (HKG: 9995, SHA: 688331) released its 2024 financial report, recording...
RemeGen’s Taitaxipu Receives CDE Acceptance for New Indication Application in China
RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) has announced that the Center for Drug Evaluation...
RemeGen Reports 40% Revenue Growth in 2023, but Net Losses Widen Amid Pipeline Investments
RemeGen Co., Ltd (HKG: 9995; SHA: 688331), a China-based biotech firm, has unveiled its 2023...
RemeGen’s MSLN-Targeted ADC RC88 Clears to Begin Phase I/IIa Study in China
RemeGen Co., Ltd (HKG: 9995; SHA: 688331), a leading Chinese biotech firm, has announced that...
RemeGen Secures Fast-Track Designation for RC88 in Platinum-Resistant Ovarian Cancer
China-based biotech RemeGen Co., Ltd (HKG: 9995; SHA: 688331) has received fast-track designation (FTD) from...
RemeGen Ltd Receives FDA Clearance for MSLN-Targeting ADC RC88 in Gynecological Tumors
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical clearance...
RemeGen’s Telitacicept Shows Positive Phase III Results in Rheumatoid Arthritis Study
China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has announced positive results from the China...
RemeGen Ltd Reports 20.56% YOY Revenue Growth in H1 2023 Financial Results
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has released its financial report for the first...
RemeGen’s Novel Bispecific Antibody RC148 Receives Clinical Trial Approval
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical trial...
RemeGen’s Telitacicept Gains FDA Approval for Phase III Study in Myasthenia Gravis
China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has announced receiving approval from the US...
RemeGen’s Telitacicept Set for Breakthrough Therapy Designation in Myasthenia Gravis
The Center for Drug Evaluation (CDE) website indicates that China-based RemeGen Co., Ltd’s (HKG: 9995,...
RemeGen’s Telitacicept Shows Positive Results in Phase II Myasthenia Gravis Study
China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has released data from a Phase II...